- Conditions
- Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 152
- States / cities
- Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 124 more
Condition Directory
Lung Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
616
Shown on this page
12
Local recruiting
92
Local phase groups
6
Showing 1–12 of 616 matching trials for Lung Cancer.
Indexed local directory records.
Phase distribution
Phase 2 235
Phase 1 151
Not applicable 109
Phase 3 52
Early Phase 1 4
Phase 4 1
Top locations
Top sponsors
Top therapies
Indexed official records
Open in full search- Conditions
- Cancer of the Lung, Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Creve Coeur, Missouri
- Conditions
- CRC, Cancer, Colon Cancer, Colorectal Adenocarcinoma, Colorectal Cancer, Lung Cancer, MESOM, Mesothelioma, Mesothelioma, Malignant, NSCLC, NSCLC, Recurrent, Non Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Pancreas Cancer, Pancreatic Neoplasm, Rectal Cancer, Solid Tumor, Adult
- Interventions
- A2B543, A2B694, xT CDx with HLA-LOH Assay
- Biological · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Multiple Myeloma, Prostate Cancer
- Interventions
- mHealth Intervention
- Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Solid Tumor, Bladder Cancer, Breast Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Non-small Cell Lung Cancer (NSCLC), Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Cancer
- Interventions
- HER3-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 13
- States / cities
- Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more
- Conditions
- Lung Cancer, MTAP Deletion, NSCLC, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, RAS Mutation, Thoracic Cancer
- Interventions
- RMC-6236, RMC-9805, TNG462, gemcitabine/nab-paclitaxel, mFOLFIRINOX
- Drug
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 13 more
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer, Rectum Cancer, Skin Cancer
- Interventions
- Active control comparator, Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Ann Arbor, Michigan
- Conditions
- Brain Tumor, Breast Cancer, Colon Cancer, Esophageal Cancer, Gynecologic Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Oral Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Skin Cancer, Solid Tumor, Stomach Cancer, Testicular Cancer, Thyroid Cancer
- Interventions
- Brodalumab, CT scan
- Drug · Radiation
- Lead sponsor
- Brian Henick, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Deep Learning, Early Cancer Detection, Health Screening, Lung Cancer
- Interventions
- CXR-LC
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years to 77 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- Enhanced Usual Care, Pathways
- Behavioral
- Lead sponsor
- Laurie McLouth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 3,606 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Lung Cancer
- Interventions
- BMS-986507, Nivolumab, Osimertinib, Pembrolizumab, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Miami, Florida • Maywood, Illinois + 9 more
About this Lung Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lung Cancer.